{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:06:44Z","timestamp":1791526004057,"version":"4.3.4"},"reference-count":18,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["grant no. ZR2022MH261"],"award-info":[{"award-number":["grant no. ZR2022MH261"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Yantai Science and Technology Innovation Development Plan, China","award":["grant no. 2022JCYJ040"],"award-info":[{"award-number":["grant no. 2022JCYJ040"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>\nBackground\n<\/jats:title>\n<jats:p>After the introduction of anticholinergic drugs for the treatment of overactive bladder (OAB), the discovery of \u03b2-adrenergic agonists has helped reduce the side effects associated with the former. Currently, the two available medications, mirabegron and vibegron, are \u03b2-adrenergic agonists. However, clinical practitioners are still faced with the dilemma of which drug to choose.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>\nObjective\n<\/jats:title>\n<jats:p>To analyze and compare the efficacy and adverse effects of the two medications.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>\nMethods\n<\/jats:title>\n<jats:p>A literature search was conducted to identify randomized controlled trials using mirabegron and vibegron for the treatment of OAB. Databases such as PubMed, Web of Science, Cochrane Library, and Embase were searched. The search cutoff date was July 25 2024. Data extraction and quality assessment were performed using standardized methods. A meta-analysis was then conducted using RevMan software and a random-effects model, with studies weighted according to sample size and variance. Heterogeneity was assessed using the I\u00b2 statistic. All statistical analyses were performed using RevMan, and results were presented as effect sizes (e.g., mean difference or risk ratio).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>\nResults\n<\/jats:title>\n<jats:p>Three randomized controlled trials compared the safety and efficacy of mirabegron and vibegron head-to-head, involving 368 patients. The trials, each lasting 8 or 12 weeks. The trials compared the changes in various indices of the OABSS (Overactive Bladder Symptom Score) between the two drugs. The statistical methods used in the analysis included Mean Difference (MD), 95% Confidence Interval (CI), p-value, and I\u00b2 statistic. For OABSS: MD =\u2009 0.38, 95% CI =\u2009 \u2212\u20090.19 to 0.95, p =\u2009 0.28, I\u00b2 =\u2009 21%; for Q1: MD =\u2009 0.08, 95% CI =\u2009 \u2212\u20090.01 to 0.26, p =\u2009 0.31, I\u00b2 =\u2009 4%; for Q2: MD =\u2009 0.08, 95% CI =\u2009 \u2212\u20090.21 to 0.37, p =\u2009 0.67, I\u00b2 =\u2009 0%; for Q3: MD =\u2009 0.05, 95% CI =\u2009 \u2212\u20090.45 to 0.56, p =\u2009 0.90, I\u00b2 =\u2009 0%; for Q4: MD =\u2009 \u2212\u20090.21, 95% CI =\u2009 \u2212\u20090.68 to 0.27, p =\u2009 0.35, I\u00b2 =\u2009 0%. The relative risk (RR) of adverse effects between the two drugs was: RR =\u2009 0.87, 95% CI =\u2009 0.57 to 1.34, p =\u2009 0.27, I\u00b2 =\u2009 25%; for constipation: RR =\u2009 0.73, 95% CI =\u2009 0.37 to 1.43, p =\u2009 0.27, I\u00b2 =\u2009 25%; and for dry mouth: RR =\u2009 0.98, 95% CI =\u2009 0.42 to 2.30, p =\u2009 0.78, I\u00b2 =\u2009 0%.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>\nConclusion\n<\/jats:title>\n<jats:p>There appears to be no statistically significant difference in efficacy and safety between mirabegron and vibegron for OAB patients. Further high-quality prospective studies are needed to confirm these results.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0317550","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T17:54:47Z","timestamp":1744134887000},"page":"e0317550","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of efficacy and safety of mirabegron and vibegron in the treatment of Overactive Bladder (OAB) in older women: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"20","author":[{"given":"Jiankun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpeng","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyuan","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8418-5134","authenticated-orcid":true,"given":"Yuanshan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"pone.0317550.ref001","first-page":"1433","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","author":"B Haylen","journal-title":"International Urogynecology Journal (Electronic)"},{"key":"pone.0317550.ref002","first-page":"0733","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","author":"P Abrams","journal-title":"International Continence Society (Print)"},{"key":"pone.0317550.ref003","first-page":"1757","article-title":"Prevalence of overactive bladder in China, Taiwan and South Korea: Results from a cross-sectional, population-based study","author":"YC Chuang","journal-title":"Electronic"},{"key":"pone.0317550.ref004","first-page":"1464","article-title":"NICE Guidance - Urinary incontinence and pelvic organ prolapse in women: management: \u00a9 NICE (2019) Urinary incontinence and pelvic organ prolapse in women: management","journal-title":"Electronic"},{"key":"pone.0317550.ref005","first-page":"1873","article-title":"Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis","author":"C Kelleher","journal-title":"Electronic"},{"key":"pone.0317550.ref006","first-page":"1520","article-title":"Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder","author":"J Wang","journal-title":"Electronic"},{"key":"pone.0317550.ref007","first-page":"1873","article-title":"Efficacy and tolerability of mirabegron, a \u03b2(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial","author":"V Khullar","journal-title":"Electronic"},{"key":"pone.0317550.ref008","first-page":"1873","article-title":"Vibegron, a novel potent and selective \u03b2(3)-adrenoreceptor agonist, for the treatment of patients with overactive bladder: A randomized, double-blind, placebo-controlled phase 3 study","author":"M Yoshida","journal-title":"Electronic"},{"key":"pone.0317550.ref009","first-page":"1433","article-title":"Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial","author":"NA-O Wada","journal-title":"Electronic"},{"key":"pone.0317550.ref010","first-page":"1527","article-title":"Comparison of Mirabegron and Vibegron in Women With Treatment-Naive Overactive Bladder: A Randomized Controlled Study","author":"M Kinjo","journal-title":"Electronic."},{"key":"pone.0317550.ref011","first-page":"1757","article-title":"Mirabegron versus vibegron in previously untreated female patients with overactive bladder: A randomized, single-clinic, open-label trial.","author":"HA-O Sato","journal-title":"Electronic"},{"key":"pone.0317550.ref012","first-page":"1522","article-title":"BDNF overexpression in the bladder induces neuronal changes to mediate bladder overactivity","author":"M Kashyap","journal-title":"Electronic"},{"key":"pone.0317550.ref013","first-page":"1872","article-title":"Urothelial signaling","author":"LA Birder","journal-title":"Electronic"},{"key":"pone.0317550.ref014","first-page":"1527","article-title":"Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder","author":"P Van Kerrebroeck","journal-title":"Electronic"},{"key":"pone.0317550.ref015","first-page":"2724","article-title":"Adverse events related to antimuscarinics and beta-3-agonist: \u201creal-life\u201d data from the Eudra-Vigilance Database","author":"C DEN","journal-title":"Eudra-Vigilance Database(Electronic)"},{"key":"pone.0317550.ref016","first-page":"1744","article-title":"Evaluating vibegron for the treatment of overactive bladder","author":"T Rechberger","journal-title":"Electronic"},{"key":"pone.0317550.ref017","first-page":"1757","article-title":"Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis","author":"WA-O He","journal-title":"Electronic"},{"key":"pone.0317550.ref018","first-page":"1873","article-title":"Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison","author":"K Maman","journal-title":"Electronic"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0317550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T17:54:48Z","timestamp":1744134888000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0317550"}},"subtitle":[],"editor":[{"given":"Richard Kao","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0317550","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]}}}